Mumbai, April 8 -- The approved product is indicated for the treatment of adults with type-2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type-2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.

Dapagliflozin Tablets will be manufactured at Biocon's FDA-approved facilities, in compliance with global quality and regulatory standards.

"This approval further strengthens Biocon's expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the company's integrated approach to addressing the evolving needs of...